Arbuckle Stuart A 4

4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 6, 2025

Insider Transaction Report

Form 4
Period: 2025-02-04
Arbuckle Stuart A
EVP\Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2025-02-04+14,62464,315 total
  • Award

    Common Stock

    2025-02-04+8,44872,763 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    140
Footnotes (2)
  • [F1]Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025.
  • [F2]Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025.

Documents

1 file
  • 4
    wk-form4_1738876713.xmlPrimary

    FORM 4